Business
Wave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics Conference
CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering
About this update from Wave Life Sciences Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will present preclinical data from its SNP3-targeting Huntington’s disease (HD) program at the CHDI Foundation’s 15th Annual Huntington’s Disease Therapeutics Conference, being held February 24-27, 2020, in Palm Springs, California. The poster presentation will include preclinical in vivo and in vitro data for Wave’s investigational allele-selective stereopure oligonucleotides designed to preferentially target the mutant huntingtin (mHTT) mRNA transcript associated with a single nucleotide polymorphism (SNP3).\n Wave’s HD pipeline includes its Phase 1b/2a investigational oligonucleotides targeting SNP1 (WVE-120101) and SNP2 (WVE-120102), as well as its SNP3-targeting oligonucleotides. All of these oligonucleotides are designed to be allele-selective and preferentially lower mHTT protein while keeping the level of healthy or wild-type HTT (wtHTT) protein relatively intact. The wtHTT protein is important for neuronal function, and there is increasing evidence that it may be neuroprotective in an adult brain. Additionally, a dominant gain of function in mHTT protein and a concurrent loss of function of wtHTT protein may be important components of the pathophysiology of HD. Details of Data Presentation •Poster: Stereopure oligonucleotides for the selective silencing of mutant huntingtin Wednesday, February 26, 2020 1:00-4:00 p.m. PST About Wave Life Sciences’ Clinical Research in Huntington’s DiseaseWave is developing WVE-120101 and WVE-120102, which are investigational stereopure antisense oligonucleotides designed to selectively target the mutant huntingtin (mHTT) mRNA transcript of SNP rs362307 (SNP1) and SNP rs362331 (SNP2), respectively. SNPs are naturally occurring variations within a given genetic sequence and in certain instances can be used to distinguish between two related copies of a genetic transcript where only one is associated with the CAG expansion that leads to expression of mHTT protein. WVE-120101 and WVE-120102 are currently being investigated in early manifest HD patients in the Phase 1b/2a PRECISION-HD1 and PRECISION-HD2 studies, respectively. In December 2019, Wave...